A Review on Introduction, Importance and Applications of Peptidomimetics.
DOI:
https://doi.org/10.22270/ajprd.v12i6.1481Abstract
Peptidomimetics, a class of compounds that bridge the gap between peptides and small molecules, have emerged as a transformative class of compounds in drug discovery and therapeutics. Using information from recent studies, this review examines the importance, design approaches, uses, and potential future directions of Peptidomimetic When compared to natural peptides, peptidomimetics show superior stability, selectivity, and versatility. This increases the drug gable space and makes it possible to develop novel therapeutic modalities. Optimizing the pharmacokinetic properties and target interactions of peptidomimetics requires the application of rational design strategies, structural modifications, and synthetic methodologies. Targeting protein-protein inter actions, inhibiting enzymes, and modifying immune checkpoints are examples of diverse therapeutic applications with potential in oncology, infectious diseases, neurology, and other fields. It is the goal of future research directions to embrace interdisciplinary approaches, investigate cutting-edge fields like immunotherapy and precision medicine, and address issues like off-target effects and synthetic accessibility. Peptidomimetics has the potential to significantly transform drug discovery and advance precision medicine techniques for better patient outcomes.
Downloads
References
R.C. Milton; S.C. Milton; S.B. Kent. Science, 1992; 256:1445-1448.
Trabocchi, Andrea. "Principles and applications of small molecule peptidomimetics." Small molecule drug discovery. Elsevier, (2020). 163-195.
Farmer, P. S.; Ariëns, E. J. Speculations on the design of nonpeptidic peptidomimetics Trends Pharmacol. Sci. 1982; 3, 362– 365
Giannis, A.; Kolter, T. Peptidomimetics for receptor ligands -- discovery, developoment, and medical perspectives Angew. Chem., Int. Ed. 1993; 32:1244– 1267
Wiley, R. A.; Rich, D. H. Peptidomimetics derived from natural products Med. Res. Rev. (1993), 13: 327– 384
Gante, J. Peptidomimetics—tailored enzyme inhibitors Angew. Chem., Int. Ed. 1994;33:1699– 1720
D.J. Abraham. Burger’s Medicinal Chemistry and Drug Discovery, 6th edition, John Wiley and Sons, New Jersey, 2003; 1: 634-636.
Smith, J. etal. Strategies for the Design of Peptidomimetics. Chemical Reviews. (2019). 120(8), 3781-3810.
Patel, S.etal Therapeutic Applications of Peptidomimetics: Targeting Protein-Protein Interactions, Enzyme Inhibition, and Beyond. Nature Reviews Drug Discovery,2016; 16(12):826-843.
Doak, B. C. et al. Expanding the Druggable Space withPeptidomimetics: Beyond the Rule of 5. Chemistry & Biology, 2019; 22(9):1115-1142.
Smith, J.etal. Strategies for the Design of Peptidomimetics. Chemical Reviews, 2019; 120(8):3781-3810.
Patel, S.etal. Therapeutic Applications of Peptidomimetics: Targeting Protein-Protein Interactions, Enzyme Inhibition, and Beyond. Nature Reviews Drug Discovery, 2016; 16(12):826-843.
Brown, A. et al. Structural Diversity of Peptidomimetics: From Small Moleculesto Macrocycles. Accounts of Chemical Research, 2018; 52(10): 2804-2815.
Lee, K.etal.Challenges and Opportunities in Peptidomimetic Research. Trends in Pharmacological Sciences, 2015; 37(9):720-731.
Gupta, N. et al. Peptidomimetics: A Synthetic Tool forInhibiting Protein-Protein Interactions in Cancer. International Journal of Peptide Research and Therapeutics, 2017; 23(4):493-504.
Schafmeister, C.E.etal. Peptidomimetics in Drug Design: Discovering Peptide Mimeticsto Leadthe Way. Current Opinionin Chemical Biology,2000;4(4):445-451.
Lau, J. L. et al. Peptide and Peptidomimetic ModulatorsofProtein-ProteinInteraction:AMolecularApproach.JournalofMedicinal Chemistry,(2019). 63(1),8-32.
Sakai, N. et al. Peptidomimetics as a New Generation of Antimicrobial Agents: Current Progress. Molecules 2013;18(1):4280-4294.
Chen, L. et al. Peptidomimetics as Potential Therapeutics for Malaria. Frontiers in Chemistry 2018; 6:146.
Wu, X .etal. Peptidomimetics as Antiviral Agents: Recent Advances and Challenges. Drug Discovery Today 2019; 24(10):2011-2019.
Krchňák,V.etal. Peptidomimetics and Their Applications in Biomedical Research.Current Opinionin Biotechnology, 2002; 13(4):315-319.
Jimmidi, Ravikumar, et al. "DNA-encoded chemical libraries yield non-covalent and non-peptidic SARS-CoV-2 main protease inhibitors." Communications Chemistry 6.1 (2023): 164.
Cicaloni, Vittoria, et al. "Applications of in silico methods for design and development of drugs targeting protein-protein interactions." Current topics in medicinal chemistry 19.7 (2019): 534-554.
Kelso, Michael J., and David P. Fairlie. "Current approaches to peptidomimetics." Molecular Pathomechanisms and New Trends in Drug Research. CRC Press, 2002. 597-616.
Cescon, M., et al. "Valorization of seafood processing waste as bio-adsorbent material for water remediation." Atti del XXIX Congresso della Divisione di Chimica Analitica della Società Chimica Italiana. Società Chimica Italiana, 2022.
Isidro-Llobet, Albert, et al. "Diversity-oriented synthesis of macrocyclic peptidomimetics." Proceedings of the National Academy of Sciences 108.17 (2011): 6793-6798.
Yang, Kai-Chieh, et al. "Crystallization-Induced Flower-like Superstructures via Peptoid Helix Assembly." ACS Macro Letters 13.4 (2024): 423-428.
Panzeri, Silvia. "Synthesis and biomedical applications of novel RGD and iso DGR integrin ligands." (2016).
Wang, Junyuan, et al. "Rational design of small-sized peptidomimetic inhibitors disrupting protein–protein interaction." RSC Medicinal Chemistry (2024).
Gomari, Mohammad Mahmoudi, et al. "Peptidomimetics in cancer targeting." Molecular Medicine 28.1 (2022): 146.
Martínez, Osmel Fleitas, Harry Morales Duque, and Octávio Luiz Franco. "Peptidomimetics as potential anti-virulence drugs against resistant bacterial pathogens." Frontiers in Microbiology 13 (2022): 831037.
Borges, Pedro Henrique Oliveira, Sabrina Baptista Ferreira, and Floriano Paes Silva Jr. "Recent Advances on Targeting Proteases for Antiviral Development." Viruses 16.3 (2024): 366.
Weeks, Richard, Ammar Algburi, and Michael Chikindas. "Antimicrobial peptides and peptidomimetics for the control of antimicrobial resistance." SustainableAgriculture Reviews 49: Mitigation of Antimicrobial Resistance Vol 2. Natural and Synthetic Approaches (2021): 205-249.
Zhang, Gan, Jessica Andersen, and Guillermo Gerona-Navarro. "Peptidomimetics targeting protein-protein interactions for therapeutic development." Protein and peptide letters 25.12 (2018): 1076-1089.
Dar, Khalid B., et al. "Exploring proteomic drug targets, therapeutic strategies and protein-protein interactions in cancer: mechanistic view." Current cancer drug targets 19.6 (2019): 430-448.
Matias, Mariana, et al. "Recent highlights on molecular hybrids potentially useful in central nervous system disorders." Mini Reviews in Medicinal Chemistry 17.6 (2017): 486-517.
Litmanovich, Adi, et al. "Noncardiovascular-derived therapeutic peptidomimetics in cardiovascular disease." Peptide and Peptidomimetic Therapeutics. Academic Press, 2022. 615-654.
Hristov, Georgi, and Ivanka Stankova. "Chemical stability of new acyclovir analogues with peptidomimetics." Scientia Pharmaceutica 79.2 (2011): 259-264.
Pathak, Manish Kumar, et al. "Review on peptidomimetics: a drug designing tool." American Journal of Pharmaceutical Research 5.12 (2015).
Murali, R., et al. "Antibody like peptidomimetics as large scale immunodetection probes." Cellular and Molecular Biology (Noisy-le-Grand, France) 49.2 (2003): 209-216.
Mabonga, Lloyd, Priscilla Masamba, and Abidemi Paul Kappo. "Therapeutic peptidomimetics: targeting the undruggable space." Peptide and Peptidomimetic Therapeutics. Academic Press, 2022. 37-55.
Kuester, Katharina, and Charlotte Kloft. "Pharmacokinetics of monoclonal antibodies." Pharmacokinetics and pharmacodynamics of biotech drugs: principles and case studies in drug development (2006): 45-91.
Sidde, Lahari, C. Akhil, and C. Manikanta. "Assessment of numerous novel peptidomimetics." Journal of Integral Sciences (2022): 1-8.
Zhao, Andong, et al. "Chiral metallohelices enantioselectively target hybrid human telomeric G-quadruplex DNA." Nucleic acids research 45.9 (2017): 5026-5035.
Vij, Varun, Vandana Bhalla, and Manoj Kumar. "Hexaarylbenzene: evolution of properties and applications of multitalented scaffold." Chemical Reviews 116.16 (2016): 9565-9627.
Banavali, Nilesh K., and Alexander D. MacKerell Jr. "Free energy and structural pathways of base flipping in a DNA GCGC containing sequence." Journal of molecular biology 319.1 (2002): 141-160.
Ettari, Roberta, et al. "Inhibition of rhodesain as a novel therapeutic modality for human African trypanosomiasis." Journal of Medicinal Chemistry 56.14 (2013): 5637-5658.
Kharb, Rajeev, et al. "Therapeutic importance of peptidomimetics in medicinal chemistry." J. Chem. Pharm. Res 3.6 (2011): 173-186.
Babizhayev, Mark A. "Biological activities of the natural imidazole-containing peptidomimetics n-acetylcarnosine, carcinine and L-carnosine in ophthalmic and skin care products." Life sciences 78.20 (2006): 2343-2357.
Babizhayev, Mark A., Inna P. Khoroshilova‐Maslova, and Anne Kasus‐Jacobi. "Novel intraocular and systemic absorption drug delivery and efficacy of N‐acetylcarnosine lubricant eye drops or carcinine biologics in pharmaceutical usage and therapeutic vision care." Fundamental & clinical pharmacology 26.5 (2012): 644-678.
Duggan, Peter J., and Kellie L. Tuck. "Bioactive mimetics of conotoxins and other venom peptides." Toxins 7.10 (2015): 4175-4198.
Lenci, Elena, and Andrea Trabocchi. "Peptidomimetic toolbox for drug discovery." Chemical Society Reviews 49.11 (2020): 3262-3277.
Castro, Tarsila G., et al. "Non-Canonical Amino Acids as Building Blocks for Peptidomimetics: Structure, Function, and Applications." Biomolecules 13.6 (2023): 981.
Adelusi, Temitope Isaac, et al. "Molecular modeling in drug discovery." Informatics in Medicine Unlocked 29 (2022): 100880.
Yang, Wenzhan, et al. "The evolving druggability and developability space: chemically modified new modalities and emerging small molecules." The AAPS journal 22 (2020): 1-14.
Hassan Baig, Mohammad, et al. "Computer aided drug design: success and limitations." Current pharmaceutical design 22.5 (2016): 572-581.
Synoradzki, Kamil J., et al. "From molecular biology to novel immunotherapies and nanomedicine in uveal melanoma." Current Oncology 31.2 (2024): 778-800.
Wang, Jiajun, et al. "Antimicrobial peptides: Promising alternatives in the post feeding antibiotic era." Medicinal research reviews 39.3 (2019): 831-859.
Published
How to Cite
Issue
Section
Copyright (c) 2024 Patil Kunal, Chaudhari Anwar, Dule Priya, Garkar Rushikesh, Sayais Prashant, Patil Rutik, Jagtap Vaibhav kumar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.